Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 1.79%.

  • bioAffinity Technologies' Return on Capital Employed rose 2400.0% to 1.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.79%, marking a year-over-year increase of 2400.0%. This contributed to the annual value of 2.1% for FY2024, which is 11000.0% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Return on Capital Employed of 1.79% as of Q3 2025, which was up 2400.0% from 3.93% recorded in Q2 2025.
  • bioAffinity Technologies' Return on Capital Employed's 5-year high stood at 0.33% during Q4 2022, with a 5-year trough of 3.93% in Q2 2025.
  • Moreover, its 4-year median value for Return on Capital Employed was 1.52% (2024), whereas its average is 1.72%.
  • The largest annual percentage gain for bioAffinity Technologies' Return on Capital Employed in the last 5 years was 2400bps (2025), contrasted with its biggest fall of -23700bps (2025).
  • Quarter analysis of 4 years shows bioAffinity Technologies' Return on Capital Employed stood at 0.33% in 2022, then tumbled by -242bps to 1.15% in 2023, then tumbled by -128bps to 2.61% in 2024, then soared by 31bps to 1.79% in 2025.
  • Its last three reported values are 1.79% in Q3 2025, 3.93% for Q2 2025, and 3.68% during Q1 2025.